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Lung cancer remains the most common cause of cancer-related mortality in Scotland,
accounting for 28.9% of all cancer deaths in 2007.1 Current guidelines recommend assessment
of patient fitness and operability by a multi-disciplinary team when selecting management
options.2e6 Two of the most important prognostic markers are the stage of disease and ECOG
performance status.
The most commonly used cancer staging system is the tumour, node, metastasis (TNM)
staging system, which is maintained by the American Joint Committee on Cancer (AJCC) and
the International Union Against Cancer (UICC). In 1998, the International Association for the
Study of Lung Cancer (IASLC) established The Lung Cancer Staging Project, collecting data
on over 100,000 patients diagnosed with lung cancer between 1990e2000 worldwide, in order
to revise the 6th edition TNM staging system for non-small cell lung cancer (NSCLC).7 The 7th
edition was published in late 2009.
This review of staging in NSCLC, includes a summary of the different staging techniques
currently available and the 7th edition TNM staging system for NSCLC.8
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Lung cancer staging is the process by which the extent of the
primary tumour and the extent of tumour spread within the
body are established. The TNM staging system guides patient
management, provides information regarding prognosis and
eligibility for clinical trials, and allows international
comparisons. TNM staging is based on the characteristics of
the primary tumour (T), the degree of lymph node involve-
ment (N) and the presence or absence of metastasis (M).9,10
The combination of T, N and M descriptors are then used
to give the tumour an overall stage (IeIV), with the aim of
grouping patients into stages with similar prognoses.
Treatment options also vary from stage to stage.
There are two predominant types of staging for NSCLC11:
1. Clinical staging, ‘cTNM’
2. Pathological stage, ‘pTNM’
Clinical staging
Clinical staging is based upon careful history-taking and
physical examination, in conjunction with laboratory,
radiological and bronchoscopic findings before recommend-
ing primary therapy.
History and clinical examination
Patient history and clinical examination are used to eluci-
date features suspicious of locally advanced or metastatic
disease, as well as determining patient fitness and comorbid
disease, whichmay impact upon treatment options. Patients
often present with multiple symptoms, both respiratory and
constitutional. The most common presenting symptom is
cough, accounting for up to 75% of all presentations.12 A
meta-analysis by Toloza et al13 assessing the accuracy of
clinical detection of brain, abdominal and skeletal metas-
tases using history, clinical examination and bloodinvestigations revealed a 0.94, 0.95 and 0.90 negative
predictive value (NPV) respectively.
Radiological investigations
Chest radiography (CXR)
All patients being evaluated for lung cancer should have
a plain chest X-ray performed to provide a baseline for future
comparison. It may also reveal features that indicate disease
stage, including pulmonary nodules, pleural effusion, rib
destruction (direct or metastatic) or an elevated hemi-
diaphragm indicating involvement of the phrenic nerve, and
thus locally advanced disease.
Computed tomography (CT)
Contrast-enhanced CT scan visualising from the base of the
neck to below the adrenal glands should be performed in all
patients being investigated for lung cancer.6 CT can deter-
mine tumour size, mediastinal and vascular invasion, and
suggest lymph node involvement. It can also determine the
presence of distant metastases and estimate the proximal
extent of the tumour within the airways. CT can provide
important anatomical information in patients being consid-
ered for surgical resection.
Limitations of CT scanning in the staging of NSCLC include
its limited reliability in differentiating between benign and
malignant mediastinal lymph node enlargement, and its
inability to detect microscopic nodal and metastatic
disease. Suspicion of lymph node metastasis on CT can be
correlated with nodal size, tumour enhancement and
tumour appearance. A short-axis diameter of>10 mm on CT
assessment of mediastinal lymph nodes is considered suspi-
cious of malignancy, with a resulting sensitivity of 57e70%
and a specificity of 59e82%.13e16 Malignant nodes typically
show similar attenuation to surrounding mediastinal blood
vessels and exhibit little or no evidence of calcification. In
addition, appearances of a solid or spiculated primary mass
in comparison to a ground glass opacity, or peak enhance-
ment >110 Houndsfield Units (HU) and net enhancement
Staging of non-small cell 1769>60e70HU on dynamic CT is considered to indicate a greater
likelihood of lymph node metastasis.17,18 Thus, CT remains
a valuable tool for evaluating the T and M descriptors but is
relatively poor at evaluating the N descriptor in NSCLC, and
in the majority has been superseded by newer imaging
techniques such as PET-CT and minimally invasive sampling
techniques such as Endobronchial ultrasound guided FNA
(EBUS).
Integrated positron emission tomography-computed
tomography (PET-CT)
Occult disease can be detected by the use of integrated PET-
CT using the tracer 18Fluoro-Deoxy-Glucose (FDG). Lung
cancer cells have high metabolic activity and therefore
increased glycolysis, hexokinase activity and expression of
glucose transporter-1 receptors compared with surrounding
normal cells. This results in increased uptake of FDG in
cancer cells. PET-CT is used to confirm staging, detecting
metabolically active intrathoracic lymph nodes, including
those of normal size (<8 mm on PET-CT) and any occult
distant metastatic disease, thereby potentially avoiding
futile thoracotomy.
The PLUS trial,19 a multi-centre randomised controlled
trial (RCT) comparing conventional work-up with conven-
tional work-up plus PET found that the additional use of
PET-CT reduced futile thoracotomy rates by 20%. Meta-
analyses have shown that FDG-PET is more sensitive than CT
scanning for the detection of mediastinal disease, with
sensitivities of 85% using PET in comparison to 61% using CT
scanning.20 A further study found that integrated PET-CT
provided a sensitive (98% sensitivity, in comparison with
86% with CT scanning alone and 94% with PET scanning
alone) although not specific (44% specificity) means of
detecting mediastinal lymph node involvement in NSCLC.21
PET scanning should not be used on its own as it provides
inadequate information on the anatomic location of
increased FDG uptake. The integrated use of PET-CT
combines metabolic and morphologic data, allowing
anatomical localisation of disease. False positives can arise
from increased FDG uptake secondary to inflammation,
infection or infarction. False negatives do occur and conse-
quently current guidelines recommend the use of invasive
staging to confirm radiographic stage in patients with
discrete nodal enlargement (>10 mm on PET-CT) or a cen-
trally located tumour, regardless of PET-CT result.22 PET-CT
has limited use in the detection of brain metastases as
normal brain tissue relies on glucose metabolism and
therefore has physiologically high levels of FDG uptake.
Lesions with increased FDG uptake should be biopsied as use
of PET-CTwill result in an up-staging of 15e20% of patients in
comparison to CTscanning alone; it is therefore important to
exclude false positive PET-CT results given the impact that
this would have on patient treatment.23
Radionuclide bone scintigraphy
Bone scintigraphy is used to detect bone metastases in the
staging of patients with NSCLC. A retrospective study by
Cheran et al.24 in 2004 compared the accuracy of bone
scintigraphy with PET scanning in the detection of bone
metastases in lung cancer. The study included 257 patients
with a new diagnosis of lung cancer undergoing PET and
bone scan. It found that PET scanning had a highersensitivity and specificity than bone scintigraphy for the
detection of bone metastases (91% vs. 75% and 96% vs. 95%
respectively), and a higher overall accuracy (95% vs. 90%),
suggesting that PET-CT may in the future replace bone
scintigraphy as the principal modality for detecting bone
metastases in lung cancer. Significant problems with
bone scintigraphy include false positives (e.g. in osteopo-
rosis) and false negatives (when the metastatic deposits are
highly lytic).
Magnetic resonance imaging (MRI)
MRI scanning may be used in conjunction with CT scanning to
detect chest wall or mediastinal invasion or trans-
diaphragmatic spread of the tumour. Limitations in assessing
lung lesions lie in its sensitivity to artefact created by
respiration. However, a 2008 study of 165 patients25
comparing efficacy of PET-CT and whole body MRI in the
staging of NSCLC found similar rates for assessing T
descriptor (82% vs. 86% accuracy respectively), N descriptor
(70% vs. 68% respectively) and M descriptor (86% vs. 86%
respectively). MRI is the most effective modality for
detecting brain and hepatic metastases.25
Laboratory investigations
Laboratory investigations are used principally to identify
abnormalities resulting from metastatic disease, although
some tests are known to be useful as independent prog-
nostic markers, including C-reactive protein (CRP), albumin
and lactate dehydrogenase (LDH).26e29
Pathological staging
Some controversy exists about the definition of pathological
staging. Some believe that pathological stage can only be
established after complete surgical exploration of the
hemithorax and mediastinum. Others accept that patho-
logical stage is based upon histological findings that will
establish highest stage of disease. Tissue sampling provides
histopathologic data, allowing confirmation of the diagnosis.
Some methods of obtaining tissue also allow for assessment
of tumour extent within the airways and mediastinum.
Invasive staging
There are a number of different tissue sampling modalities
available. The choice of invasive test depends on the reli-
ability of the test, size and location of the primary tumour
and suspicious lymph nodes, extent of distant disease, test
availability and patient comorbid disease. Current guide-
lines21 recommend that invasive confirmation of clinical
stage is required for patients with discrete mediastinal
lymph node enlargement, patients with a central tumour or
N1 lymph node enlargement on imaging and those with a left
upper lobe primary tumour.
Currently available tissue sampling modalities include:
1. Flexible bronchoscopy.
Flexible bronchoscopy has a different yield for
obtaining a diagnostic specimen depending on the
sampling technique used and the location of the
primary tumour. Sampling techniques utilised include
1770 S. Tsim et al.endobronchial biopsy, bronchial brushing and bronchial
washing, which have a sensitivity of 74%, 59% and 48%
respectively in endobronchial disease. For peripheral
lesions, brushing has a sensitivity of 52%, trans-
bronchial biopsy has a sensitivity of 46% and bron-
choalveolar lavage (BAL) has a sensitivity of 43%.30
Flexible bronchoscopy has a better yield for obtaining
a diagnostic specimen in patients with a central tumour
in comparison to patients with peripheral tumours
2. Blind transbronchial fine needle aspiration (TBNA).
TBNA is used most frequently to biopsy subcarinal
nodes (station 7). It has an overall sensitivity of 78% and
a false negative rate of approximately 28%.22 This rela-
tively high false negative rate means that additional
confirmatory staging procedures are recommended
following a negative TBNA result
3. Endobronchial ultrasound (EBUS) e guided biopsy.
High mediastinal, upper and lower paratracheal,
subcarinal and hilar lymph nodes (stations 1e4, 7, 10
and 11) are accessible using EBUS. It has an overall
sensitivity of 90% and a false negative rate of 24%22
EBUS-guided biopsy is being utilised with increasing
frequency in mediastinal staging. When compared to
blind TBNA, EBUS-guided biopsy has a high sensitivity
and negative predictive value in diagnosing mediastinal
metastasis (76e78% sensitivity, 71e72% NPV versus 90%
sensitivity, 76% NPV). It also has a relatively good
performance in comparison to cervical mediastino-
scopy, which has 78e81% sensitivity, 91% NPV. EBUS has
the advantage over mediastinoscopy in that it is a less
invasive procedure, does not require a general anaes-
thetic and as a result has a lower morbidity and
mortality rate associated. However, there remains
limited access to EBUS in the UK.
4. CT/US-guided percutaneous needle biopsy
Transthoracic needle biopsy has an overall sensi-
tivity of approximately 90%.22
5. Mediastinoscopy
Mediastinoscopy has long been regarded the gold
standard for assessing disease in enlarged mediastinal
lymph nodes.22 It is performed under general anaes-
thetic, usually as a day case. Mediastinal lymph nodes
are accessed via an incision just superior to the
suprasternal notch, using a mediastinoscope. This
technique has an average sensitivity of 80% and a false
negative rate of approximately 10%. Approximately
half of these false negatives resulted from disease in
nodal stations inaccessible to mediastinoscopy: poste-
rior subcarinal (station 7), inferior mediastinal (stations
8 and 9), aortopulmonary window (station 5) and
anterior mediastinal nodes (station 6).
6. Video-assisted thoracic surgery (VATS) or thoracoscopy
VATS is usually done under general anaesthetic and
assessment is generally limited to one side of the
mediastinum, with easier access to right-sided lymph
nodes. It is predominantly used to assess pleural effu-
sions but can also be used to assess aortopulmonary (AP)
window nodes and its use has resulted in a reduction in
the use of left anterior mediastinotomies. VATS has
a sensitivity of 50e100% in patients with enlargement of
discrete mediastinal nodes, and a false negative rate of
15%.22 There are a growing number of units in the UKwhere thoracoscopy is performed by Respiratory Physi-
cians. It is performed under conscious sedation and has
the advantage in that biopsies are done with direct
visualisation, and as a result has a higher diagnostic
yield in staging of the mediastinum and pleural space
than more traditional sampling techniques of blind
needle biopsy and fluid cytology (sensitivities of 95%,
44% and 62% respectively).31,32
7. Thoracocentesis in pleural effusions
Aspiration and cytological examination of pleural
fluid in patients presenting with suspected malignant
pleural effusion provides a diagnostic yield of approx-
imately 60%.30 One study demonstrated a diagnostic
rate of 44% with blind (Abrams) biopsy, rising to 74%
when combined with pleural fluid cytology, however, in
this study the diagnostic rate from medical thoraco-
scopy was 95%32 and it is because of this increased
diagnostic difference that many clinicians favour
a thoracoscopic approach.
8. Anterior mediastinotomy (Chamberlain procedure)
Left upper lobe primary tumours have a predilection
for metastasising to AP window nodes (station 5).
Anterior mediastinotomy can be used to assess these
nodes via an incision in the second or third intercostal
space. When used in conjunction with cervical media-
stinoscopy, it has an overall sensitivity of 87% and
a false negative rate of approximately 10% for assessing
mediastinal lymph node disease.22
9. Oesophageal endoscopic ultrasound with needle aspi-
ration (EUS)
This technique is limited by its poor access to high
and low paratracheal nodes (nodal stations 2R, 2L, 4R
and 4L), which are the nodes most commonly involved
in NSCLC. However it is useful in assessing the nodal
stations inaccessible to EBUS (nodal stations 8 and 9). It
has an overall sensitivity of 84% with a false negative
rate of 19%.22
10. Resection with systematic nodal dissection
Goldstraw et al.33 conducted a study evaluating 227
patients who underwent pulmonary resection with
systematic nodal dissection. All patients had a clinical
stage of cT1-3, cN0-1 following CT, bone scan and, if
lymph nodes were found to be >1.5 cm on CT, cervical
mediastinoscopy. N2 disease was found in 18% of
patients who subsequently underwent resection with
systematic nodal dissection, highlighting the impor-
tance of systematic nodal dissection, at time of
resection, for accurate staging of NSCLC. At present,
all cases of NSCLC undergoing surgical management
should undergo systematic nodal dissection.TNM staging: the 7th edition
The 7th edition TNM classification of NSCLC has recently
been published.34 It follows findings from The Lung Cancer
Staging Project established in 1998 by the IASLC.8,35,36 The
new edition aims to provide a more accurate correlation
between TNM stage and statistical survival data for all
patients with lung cancer than the 6th edition.
A retrospective analysis of a database of 100,869 patients
with primary lung cancer, treated by all modalities, ranging
TNM Stage groupings & 5-year survival (%) 
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Figure 1 TNM and stage grouping e 7th edition.
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institutions in over 19 countries, between 1990 and 2000 was
conducted. Of the 100,869 cases collected in the database,
81,015 were included in the study. A number were excluded
due to unknown histology, not being a new diagnosis at point
of registration or because there was inadequate information
on the stage, treatment modality or follow-up of the
patient. Of the cases included in the study, 67,725 were
NSCLC and 13,290 were small cell lung cancers (SCLC).
Patients were followed up for five-years and survival was
measured from the date of diagnosis. Following analysis of
the survival data, a number of changes were recommended
to the TNM staging of lung cancer.
Changes to T descriptor
The study found significant differences in the five-year
survival of patients with a tumour diameter of 2 cm (53%),
3 cm (47%), 5 cm (43%), 7 cm (36%) and >7 cm (26%) and
recommended the addition of these tumour size cut-offs to
the T descriptor, further delineating the T stage into T1a/
T1b and T2a/T2b depending on the size of the primary
tumour. Tumours >7 cm in diameter were found to have
a comparable five-year survival to patients with invasion to
the chest wall or mediastinal tumour and were thus up-
staged to T3. It was also recommended that patients with
satellite nodules in the same lobe as the primary tumour
were down-staged from T4 to T3 due to comparable survival
rates with T3 tumours (28% 5-year survival). Patients with
metastatic nodules in a different lobe of the ipsilateral lung
were down-staged from M1 to T4, given their relatively
better survival rate than those with M1 disease but worse
survival than those with T3 disease.37
The N descriptor
No recommendations were made for changes to the N
descriptor following this study. The IASLC has however, since
proposed the incorporation of the fourteen regional lymph
node stations38 into six nodal zones to resolve differences
between the Naruke map,39 used largely in Asia, and the
‘Mountain-Dresler’ modification of the American Thoracic
Society map (MD-ATS)40 used largely in Northern America
and to a lesser extent Europe. Creating a universally
accepted lymph node map will allow easier comparison of
survival data between institutions and easier design and
analysis of future clinical trials in the future.
The proposed nodal zones are:
1. Upper-nodal stations 1e4
2. Aortopulmonary-nodal stations 5 and 6
3. Subcarinal-nodal station 7
4. Lower-nodal stations 8 and 9
5. Hilar-nodal stations 10 and 11
6. Peripheral-nodal stations 12e14
The IASLC Lung Cancer Staging Project found differences
in survival based upon the number of nodal zones involved
within each N descriptor.36,41 For example, patients with
any T and M0 disease had a reduced median survival time if
they had multiple N1 nodal zone involvement (31 months)versus single N1 nodal zone involvement (52 months).36,42
Similar differences are seen for N2 nodal zones, however,
the number of cases studied were too low to reach statis-
tical significance. Although no changes were made to the N
descriptor in the 7th edition, it is important to bear in mind
the significance of the number of nodal stations involved
when considering patient prognosis.
The M descriptor
Patientswithmalignantpleural effusionswereup-staged from
T4 to M1 following the finding of a comparably worse median
survival time for patientswith amalignant effusion (8months)
in comparison to patients with other aspects of a T4 tumour
(13 months). The M descriptor has been further divided into
M1aandM1b for intrathoracic anddistant spread respectively,
following the finding of a significant difference in the survival
rates of patients with distant metastasis to patients with
pleural involvement or metastasis to the contralateral lung,
1%, 6% and 3% 5-year survival respectively.43
Stage groupings
Following the alterations to the TNM descriptors, changes
to the stage groupings were also recommended, based on
comparative survival rates for each TNM subset (Fig. 1 and
Tables 1 and 2).
Limitations of the 7th edition include the non-represen-
tation of Africa, South America and the Indian Subcontinent
and theunder-representation of Russia, Chinaand Indonesia.
In addition, the time period that was studied largely pre-
dated thewidespread use of PET-CTscanning and the current
widespread use of PET-CT for staging is likely to make
a significant impact on staging results for future revisions.
Staging of small cell lung cancer (SCLC)
Approximately 15% of all lung cancers are small cell. Previ-
ously SCLC has been classified as limited disease or extensive
disease, with tumour burden, including nodal metastases,
confined to one hemithorax constituting limited disease. All
other patients were classified as having extensive
disease.23,44 However, the IASLC group analysed 349 cases of
SCLC, which had been surgically resected, and therefore had
Table 1 TNM staging of NSCLC 7th edition.35
Primary tumour (T)
 T1 e Tumour 3 cm in diameter, surrounded by lung or visceral pleura, without invasion more
proximal than lobar bronchus.
 T1a e Tumour 2 cm in diameter.
 T1b e Tumour >2 cm but 3 cm in diameter.
 T2 e Tumour >3 cm but 7 cm in diameter, or tumour with any of the following features:
B Involvement of the main bronchus 2 cm distal to the carina.
B Invasion of visceral pleura.
B Associated atelectasis or obstructive pneumonitis that does not involve the entire lung.
 T2a e Tumour 5 cm in diameter.
 T2b e Tumour >5 cm but 7 cm in diameter.
 T3 e Tumour >7 cm in diameter, or tumour with any of the following features:
B Direct invasion of the chest wall, diaphragm, phrenic nerve.
B Direct invasion of mediastinal pleura or parietal pericardium.
B Associated atelectasis or obstructive pneumonitis of the entire lung.
B Tumour within the main bronchus <2 cm to the carina, without involvement of the carina.
B Satellite tumour nodules in the same lobe.
 T4 e Tumour of any size that has any of the following features:
B Invasion of the mediastinum.
B Invasion the heart or great vessels.
B Invasion of the trachea, oesophagus or recurrent laryngeal nerve.
B Invasion of a vertebral body or carina.
B Separate tumour nodules in a different ipsilateral lobe.
Regional lymph nodes (N)
 N0 e No regional lymph node metastasis.
 N1 e Involvement of ipsilateral hilar or peri-bronchial nodes.
 N2 e Involvement of ipsilateral mediastinal or subcarinal nodes.
 N3 e Involvement of contralateral mediastinal or hilar nodes, OR involvement of ipsilateral/contralateral scalene or
supraclavicular nodes.
Distant Metastasis (M)
 M0 e No distant metastasis.
 M1 e Distant metastasis present.
 M1a e Separate tumour nodule(s) in a contralateral lobe or tumour with pleural nodules or malignant pleural/
pericardial effusion.
 M1b e Distant metastases.
1772 S. Tsim et al.a pathological TNM staging information.45 They found
a correlation between TNM stage and survival rates, in
particular, nodal status appeared to have the strongestTable 2 Stage Grouping e cTNM subsets 7th edition.8
Stage cTNM Subset Five-year Survival
0 Carcinoma in situ
IA T1a/T1b, N0M0 50e80%
IB T2aN0M0 47%









Any T, N3, M0
IV Any T, Any N, M1a/M1b 2%correlation with disease survival. As a result, they have
proposed the usage of the revised TNM system in the staging
of SCLC in place of the historical limited or extensive disease
stage. Despite this recommendation, the TNM system is still
not being as widely adopted for the staging of SCLC
compared to NSCLC.
Conclusion
Accurate staging of non-small cell lung cancer and assess-
ment of a patient’s performance status is vital as it provides
the framework for patient management. The 7th edition
TNM staging system, illustrates the prognostic importance
in staging accurately the mediastinum and pleural space.46
The pleural space has often been poorly evaluated and this
must change and as a consequence medical thoracoscopy
will become an increasingly valuable method of evaluating
malignant pleural effusions and should be incorporated
early into the diagnostic and staging pathways.
Similarly it is essential that the mediastinum is staged as
accurately as possible with the combination of PET-CT, EBUS
and/or mediastinscopy. It is essential that centres continue
Staging of non-small cell 1773to work towards providing access to EBUS to all patients with
Lung Cancer in order to accurately stage the mediastinum
where appropriate.
Recent publications have highlighted the importance of
not only accurate staging but also accurate histological
subclassification of Non-Small Cell Lung Cancers as this will
further determine specific treatment modalities. Recent
NICE guidelines47 have recommended pemetrexed and
cisplatin in combination for the first-line treatment of NSCLC
confirmed to be adenocarcinoma or large-cell carcinoma.
This was following a non-inferiority randomised control trial
comparing the combination of pemetrexed and cisplatin
versus the combination of gemcitabine and cisplatin in the
treatment of patients with both squamous and non-squa-
mous NSCLC. This trial demonstrated improved survival in
patients with non-squamous NSCLC treated with peme-
trexed/cisplatin chemotherapy.48
The future of NSCLC management will involve the analysis
and revision of existing treatment protocols according to the
new staging system and the continued expansion and analysis
of the central database for future revisions. It is imperative
that wherever possible, multi-disciplinary teams strive to
obtainaccuratepathological staging forall casesofNSCLCand
to build all available staging techniques into their diagnostic
pathways to direct patient management and clinical trials,
and to allow effective communication between centres.
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